Angelini Pharma保证了Curevvers第一阶段阿尔茨海默氏综合体CV-01的独家选择权。 Angelini Pharma secures exclusive option for Cureverse's Phase 1 Alzheimer's compound, CV-01.
Angelini Pharma与Cureveven Inc. 达成了CV-01的独家选择协议。 CV-01是第一阶段的化合物,旨在治疗像阿尔茨海默氏病这样的脑健康疾病。 Angelini Pharma has secured an exclusive option agreement with Cureverse Inc. for CV-01, a Phase 1 compound aimed at treating brain health diseases like Alzheimer’s. 安杰利尼将带头推动发展,并在特定亚洲区域之外拥有全球权利。 Angelini will spearhead development and hold global rights outside of specific Asian regions. Cureverse 将获得总额高达 3.6 亿美元的预付款和里程碑付款，以及未来销售的特许权使用费。 Cureverse will receive upfront and milestone payments totaling up to $360 million, plus royalties on future sales. 这一伙伴关系力求加强全球脑健康状况的治疗选择。 This partnership seeks to enhance treatment options for brain health conditions globally.